Impact News +++ Übernahme: CoreWeave übernimmt Core Scientific – Aktien rauschen ab! (Wallstreet-Online) +++ CORE SCIENTIFIC Aktie -4,23%

RIGEL PHARMACEUTICALS Aktie

>RIGEL PHARMA Aktienkurs

16.1 EUR (Tradegate)

Ask: 16.4 EUR / 365 Stück

Bid: 15.8 EUR / 380 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

RIGEL PHARMA Aktie über LYNX handeln

Intraday

1 Jahr

>RIGEL PHARMA Performance

1 Woche: -4,2%

1 Monat: -10,2%

3 Monate: +3,9%

6 Monate: -5,6%

1 Jahr: 0%

laufendes Jahr: +0,6%

>RIGEL PHARMACEUTICALS Aktie

Name:

RIGEL PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US7665597024 / A40EFY

Symbol/ Ticker:

RI2 (Frankfurt) / RIGL (NASDAQ)

Kürzel:

FRA:RI2, ETR:RI2, RI2:GR, NASDAQ:RIGL

Index:

Webseite:

https://www.rigel.com/

Marktkapitalisierung:

316.18 Mio. EUR

Umsatz:

175.72 Mio. EUR

EBITDA:

40.11 Mio. EUR

Gewinn je Aktie:

1.557 EUR

Schulden:

87.44 Mio. EUR

Liquide Mittel:

66.71 Mio. EUR

Umsatz-/ Gewinnwachstum:

80.6% / -

KGV/ KGV lG:

10.05 / 6.4

KUV/ KBV/ PEG:

1.85 / 20.21 / -

Gewinnm./ Eigenkapitalr.:

18.31% / -

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

RIGEL PHARMACEUTICALS, RIGEL PHARMA, RIGEL PHARMACEUTICAL

Letzte Datenerhebung:

07.07.25

>RIGEL PHARMA Eigentümer

Aktien: 17.87 Mio. St.

f.h. Aktien: 14.97 Mio. St.

Insider Eigner: 2.66%

Instit. Eigner: 79.26%

Leerverk. Aktien: 11.9%

>RIGEL PHARMA Peer Group

CATHETER PRECISION

GRAIL INC

HEALTHCARE SERVICES GROUP

HOYA CORP ADR

NOVABAY

NUCANA

PALISADE BIO

SERINA THERAPEUTICS

STARPHARMA ADR

THERIVA

>RIGEL PHARMA Chart & Kurs - NASDAQ

>RIGEL PHARMA News

07.07.25 - 14:06	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., July 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and......

28.05.25 - 14:09	Rigel to Present at the Jefferies Global Healthcare Conference (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., May 28, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview......

22.05.25 - 23:21	Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress (PR Newswire)
	Final data from the GAVRETO® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors Supportive data for REZLIDHIA® (olutasidenib) utilization in patients with mIDH1 R/R AML SOUTH SAN FRANCISCO, Calif., May 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals,......

07.05.25 - 05:18	Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 01:00	Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates (Zacks)
	Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

05.05.25 - 23:27	Rigel Pharmaceuticals Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.04.25 - 14:09	Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., April 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Rigel senior management will follow the announcement with a live......

04.04.25 - 14:09	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., April 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and......

27.03.25 - 15:07	Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma (AFX)
	WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc.......

27.03.25 - 13:09	Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., March 27, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. (collectively "Annora") resolving patent......

10.03.25 - 13:09	Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing......

05.03.25 - 01:00	Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
	Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

04.03.25 - 22:42	Rigel Pharmaceuticals Inc. Q4 Profit Advances (AFX)
	WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals Inc. (RIGL) released earnings for its fourth quarter that increased from the same period last yearThe company's bottom line came in at $14.34 million, ......

04.03.25 - 22:06	Rigel Pharmaceuticals GAAP EPS of $0.80 beats by $0.18, revenue of $57.6M in-line (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.02.25 - 21:15	Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings? (Zacks)
	Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their portfolio....

25.02.25 - 14:06	Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update (PR Newswire)
	SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2024 financial results after market close on Tuesday, March 4, 2025. Rigel senior management will follow the......

24.02.25 - 17:30	RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell? (Zacks)
	Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. We believe there is more room for growth....

07.02.25 - 07:01	Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Rigel Pharmaceuticals im Wert von 44457 USD (Insiderkauf)
	Santos, David A. - Vorstand - Tag der Transaktion: 2025-02-04...

07.02.25 - 07:01	Insiderhandel: EVP, GC, CCO & Corp Sec verkauft Aktien von Rigel Pharmaceuticals im Wert von 29359 USD (Insiderkauf)
	Furey, Raymond J. - Vorstand - Tag der Transaktion: 2025-02-05...

07.02.25 - 07:01	Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Rigel Pharmaceuticals im Wert von 39379 USD (Insiderkauf)
	Santos, David A. - Vorstand - Tag der Transaktion: 2025-02-05...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Es geht nichts über ein ruhiges Leben, wie der Mann sagte, als er die Stelle eines Leuchtturmwärters annahm. - Charles Dickens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram